|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
146,000,000 |
Market
Cap: |
16.15(B) |
Last
Volume: |
2,848,715 |
Avg
Vol: |
1,327,950 |
52
Week Range: |
$92.79 - $212.65 |
|
Level
I Sector: |
Information Technology |
Level
II Sector: |
Electronics |
Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 11.4 |
Insider 6 Months : 11.4 |
Insider 3/6 Months : 23.2 |
|
Guru Rank Number : 691 |
Guru Rank Value : 2.3 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
7,330 |
7,330 |
7,330 |
7,330 |
Total Buy Value |
$991,672 |
$991,672 |
$991,672 |
$991,672 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
0 |
0 |
6,815 |
22,740 |
Total Sell Value |
$0 |
$0 |
$1,357,080 |
$4,648,975 |
Total People Sold |
0 |
0 |
2 |
3 |
Total Sell Transactions |
0 |
0 |
5 |
17 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-10-19 |
4 |
AS |
$410.42 |
$1,204,972 |
D/D |
(2,926) |
10,531 |
|
-20% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-10-12 |
4 |
AS |
$407.29 |
$1,197,350 |
D/D |
(2,926) |
13,457 |
|
-22% |
|
Reeves Kathryne Gambrell |
SVP, Chief Marketing Officer |
|
2021-10-05 |
4 |
D |
$387.98 |
$32,202 |
D/D |
(83) |
2,484 |
|
- |
|
Goswami Joydeep |
SVP Corp Business Development |
|
2021-10-05 |
4 |
D |
$387.98 |
$44,618 |
D/D |
(115) |
4,053 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-09-28 |
4 |
AS |
$418.04 |
$41,804 |
D/D |
(100) |
41,356 |
|
-14% |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-09-22 |
4 |
AS |
$436.69 |
$137,121 |
I/I |
(314) |
4,972 |
|
-18% |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-08-30 |
4 |
AS |
$463.50 |
$139,050 |
D/D |
(300) |
41,456 |
|
-21% |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-08-23 |
4 |
AS |
$489.10 |
$153,577 |
I/I |
(314) |
5,286 |
|
-20% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-08-18 |
4 |
D |
$510.61 |
$5,080,059 |
D/D |
(9,949) |
16,383 |
|
- |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-08-18 |
4 |
A |
$510.61 |
$11,056,238 |
D/D |
21,653 |
26,332 |
|
- |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2021-08-04 |
4 |
AS |
$500.00 |
$186,000 |
D/D |
(372) |
3,757 |
|
-25% |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-08-04 |
4 |
AS |
$500.00 |
$500,000 |
D/D |
(1,000) |
41,756 |
|
-25% |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-07-28 |
4 |
AS |
$486.41 |
$145,923 |
D/D |
(300) |
42,743 |
|
-29% |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-07-22 |
4 |
AS |
$482.23 |
$151,420 |
I/I |
(314) |
5,576 |
|
-24% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-07-07 |
4 |
AS |
$477.59 |
$257,421 |
D/D |
(539) |
4,679 |
|
-19% |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-07-05 |
4 |
D |
$474.85 |
$135,332 |
D/D |
(285) |
5,218 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-06-28 |
4 |
AS |
$478.95 |
$143,685 |
D/D |
(300) |
43,043 |
|
-13% |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2021-06-24 |
4 |
AS |
$475.00 |
$237,500 |
D/D |
(500) |
4,111 |
|
-11% |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-06-22 |
4 |
AS |
$461.01 |
$144,757 |
I/I |
(314) |
5,890 |
|
-11% |
|
Febbo Phillip G. |
SVP Chief Medical Officer |
|
2021-06-11 |
4 |
AS |
$446.17 |
$447,589 |
D/D |
(1,000) |
4,461 |
|
-9% |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2021-06-10 |
4 |
AS |
$450.00 |
$225,000 |
D/D |
(500) |
4,611 |
|
-9% |
|
Dorsa Caroline |
Director |
|
2021-06-10 |
4 |
AS |
$450.00 |
$450,000 |
D/D |
(1,000) |
8,501 |
|
-9% |
|
Arnold Frances |
Director |
|
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
881 |
11,808 |
|
- |
|
Epstein Robert S |
Director |
|
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
881 |
6,424 |
|
- |
|
Siegel Susan E |
Director |
|
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
881 |
5,596 |
|
- |
|
3455 Records found
|
|
Page 8 of 139 |
|
|